Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug

The FDA approved daraxonrasib, the first targeted oral therapy for metastatic pancreatic adenocarcinoma, based on a trial showing it doubled median overall survival versus chemotherapy and had a better safety profile.

This Wire brief sits within Fusion42's coverage of Biotech.